|
PTC Therapeutics, Inc. (PTCT) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
PTC Therapeutics, Inc. (PTCT) Bundle
Save time and improve precision with our PTC Therapeutics, Inc. (PTCT) DCF Calculator! Equipped with real Apple data and customizable assumptions, this tool allows you to forecast, analyze, and value PTC Therapeutics, Inc. (PTCT) like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 307.0 | 380.8 | 538.6 | 698.8 | 937.8 | 1,241.3 | 1,643.0 | 2,174.6 | 2,878.3 | 3,809.7 |
| Revenue Growth, % | 0 | 24.04 | 41.45 | 29.75 | 34.2 | 32.36 | 32.36 | 32.36 | 32.36 | 32.36 |
| EBITDA | -191.4 | -297.0 | -374.4 | -367.8 | -330.3 | -739.1 | -978.3 | -1,294.8 | -1,713.8 | -2,268.4 |
| EBITDA, % | -62.34 | -78 | -69.52 | -52.63 | -35.22 | -59.54 | -59.54 | -59.54 | -59.54 | -59.54 |
| Depreciation | 36.1 | 49.6 | 71.5 | 128.8 | 236.6 | 202.9 | 268.5 | 355.4 | 470.4 | 622.6 |
| Depreciation, % | 11.75 | 13.02 | 13.28 | 18.44 | 25.23 | 16.34 | 16.34 | 16.34 | 16.34 | 16.34 |
| EBIT | -227.4 | -346.6 | -446.0 | -496.6 | -566.9 | -942.0 | -1,246.8 | -1,650.2 | -2,184.2 | -2,891.0 |
| EBIT, % | -74.09 | -91.02 | -82.8 | -71.07 | -60.45 | -75.89 | -75.89 | -75.89 | -75.89 | -75.89 |
| Total Cash | 686.6 | 1,103.7 | 773.4 | 410.7 | 876.7 | 1,122.8 | 1,486.1 | 1,967.0 | 2,603.5 | 3,445.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 55.5 | 69.9 | 110.5 | 155.6 | 161.0 | 239.3 | 316.8 | 419.3 | 555.0 | 734.5 |
| Account Receivables, % | 18.09 | 18.37 | 20.51 | 22.27 | 17.17 | 19.28 | 19.28 | 19.28 | 19.28 | 19.28 |
| Inventories | 19.3 | 18.7 | 15.9 | 21.8 | 30.6 | 50.9 | 67.4 | 89.2 | 118.1 | 156.3 |
| Inventories, % | 6.28 | 4.91 | 2.94 | 3.12 | 3.26 | 4.1 | 4.1 | 4.1 | 4.1 | 4.1 |
| Accounts Payable | 10.3 | 18.7 | 23.0 | 27.3 | 6.0 | 42.4 | 56.2 | 74.3 | 98.4 | 130.2 |
| Accounts Payable, % | 3.36 | 4.9 | 4.28 | 3.9 | 0.64458 | 3.42 | 3.42 | 3.42 | 3.42 | 3.42 |
| Capital Expenditure | -45.4 | -56.0 | -85.3 | -152.5 | -120.6 | -198.7 | -263.0 | -348.0 | -460.7 | -609.7 |
| Capital Expenditure, % | -14.8 | -14.7 | -15.84 | -21.82 | -12.86 | -16.01 | -16.01 | -16.01 | -16.01 | -16.01 |
| Tax Rate, % | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 | 9.98 |
| EBITAT | -238.5 | -376.9 | -450.7 | -472.5 | -510.3 | -914.0 | -1,209.8 | -1,601.3 | -2,119.4 | -2,805.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -312.4 | -388.7 | -497.9 | -543.0 | -429.8 | -972.1 | -1,284.5 | -1,700.1 | -2,250.2 | -2,978.4 |
| WACC, % | 6.77 | 6.77 | 6.77 | 6.66 | 6.54 | 6.7 | 6.7 | 6.7 | 6.7 | 6.7 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7,327.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -3,038 | |||||||||
| Terminal Value | -64,596 | |||||||||
| Present Terminal Value | -46,700 | |||||||||
| Enterprise Value | -54,028 | |||||||||
| Net Debt | 1,635 | |||||||||
| Equity Value | -55,663 | |||||||||
| Diluted Shares Outstanding, MM | 75 | |||||||||
| Equity Value Per Share | -743.78 |
What You Will Get
- Real PTC Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for PTC Therapeutics, Inc. (PTCT).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to PTC Therapeutics, Inc. (PTCT).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on PTC Therapeutics, Inc. (PTCT)’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for PTC Therapeutics, Inc. (PTCT).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for PTC Therapeutics, Inc. (PTCT).
Key Features
- Customizable Drug Development Parameters: Adjust essential inputs such as clinical trial timelines, market potential, and R&D expenditures.
- Real-Time Valuation Insights: Instantly computes intrinsic value, NPV, and other financial metrics.
- High-Precision Accuracy: Utilizes PTC Therapeutics’ actual financial data for credible valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Remove the complexity of constructing detailed valuation models from the ground up.
How It Works
- Download: Obtain the pre-configured Excel file containing PTC Therapeutics, Inc.'s (PTCT) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment approach.
Why Choose PTC Therapeutics, Inc. (PTCT)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Results: Clinical trials demonstrate significant efficacy and safety profiles.
- Patient-Centric Approach: Focused on improving the quality of life for patients and their families.
- Expert Team: Led by industry professionals with extensive experience in biotechnology.
- Commitment to Research: Continuous investment in research and development for future advancements.
Who Should Use This Product?
- Investors: Assess PTC Therapeutics' (PTCT) fair value to inform investment choices.
- CFOs: Utilize a sophisticated DCF model for accurate financial reporting and analysis.
- Consultants: Easily modify the template for client valuation reports.
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms.
- Educators: Employ it as a resource to teach valuation methods in finance courses.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for PTC Therapeutics, Inc. (PTCT).
- Real-World Data: PTC Therapeutics’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to PTC Therapeutics, Inc. (PTCT).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results related to PTC Therapeutics, Inc. (PTCT).